In patients with type 2 diabetes on multidose insulin injections (MDI), randomization to treatment with the GLP-1 RA albiglutide reduced the number of prandial insulin injections, improved glycemic control, led to weight loss, and resulted in less hypoglycemia when compared with continuation of MDI without albiglutide [9]. This evidence concerns the gene GCG and Hypoglycemia.